Varicella Zoster (HHV-3) Infections - Pipeline Insight, 2020
This report can be delivered to the clients within 24-48 Hours
DelveInsight’s, “Varicella Zoster Infections– Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Varicella Zoster Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Varicella Zoster Infections: Overview
Varicella-zoster virus (VZV) is a pathogenic human alpha-herpesvirus that causes chickenpox (varicella) as a primary infection, which usually occurs in children in locales where vaccination is not practiced. Following the primary infection, this neurotropic virus becomes latent, primarily in neurons in peripheral autonomic ganglia throughout the entire neuroaxis including dorsal root ganglia (DRG), cranial nerve ganglia such as the trigeminal ganglia (TG), and autonomic ganglia including those in the enteric nervous system.
Symptoms
The symptoms of Varicella-zoster Infections include:
The diagnosis of VZV infection is usually made clinically by the appearance of the skin rash. In confusing or unusual appearing cases, the diagnosis may be made by identifying VZV DNA in skin lesions by PCR. Culture of VZV from skin lesions may also be used, but it is more expensive, takes more time, is poorly available, and is less sensitive than PCR.
Treatment
Severe varicella may be prevented to some extent by administration of passive immunization with VariZig, a form of immunoglobulin containing high titers of antibodies to VZV; passive immunization should be administered as soon as possible after a recognised close exposure to VZV in a high-risk person who has never had varicella. Patients who develop zoster should be treated as soon as possible with acyclovir, famciclovir, or valacyclovir, which are administered orally. If zoster is severe, especially in immunocompromised patients, intravenous acyclovir can be administered, especially at the start of treatment surgery. Foscarnet is used to treat VZV infections that are resistant to ACV; the drug inhibits synthesis of VZV DNA polymerase.
Varicella-zoster Infections Emerging Drugs Chapters
This segment of the Varicella-zoster Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Varicella-zoster Infections Emerging Drugs
Further product details are provided in the report……..
Varicella-zoster Infections: Therapeutic Assessment
This segment of the report provides insights about the different Varicella-zoster Infections drugs segregated based on following parameters that define the scope of the report, such as:
Varicella-zoster Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Varicella-zoster Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Varicella-zoster Infections drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Varicella Zoster Infections– Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Varicella Zoster Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Varicella Zoster Infections: Overview
Varicella-zoster virus (VZV) is a pathogenic human alpha-herpesvirus that causes chickenpox (varicella) as a primary infection, which usually occurs in children in locales where vaccination is not practiced. Following the primary infection, this neurotropic virus becomes latent, primarily in neurons in peripheral autonomic ganglia throughout the entire neuroaxis including dorsal root ganglia (DRG), cranial nerve ganglia such as the trigeminal ganglia (TG), and autonomic ganglia including those in the enteric nervous system.
Symptoms
The symptoms of Varicella-zoster Infections include:
- Vesicular pruritic rash mainly on the trunk, head, and face
- Extremities are spared
- Malaise
- Fever
- Fatigue
The diagnosis of VZV infection is usually made clinically by the appearance of the skin rash. In confusing or unusual appearing cases, the diagnosis may be made by identifying VZV DNA in skin lesions by PCR. Culture of VZV from skin lesions may also be used, but it is more expensive, takes more time, is poorly available, and is less sensitive than PCR.
Treatment
Severe varicella may be prevented to some extent by administration of passive immunization with VariZig, a form of immunoglobulin containing high titers of antibodies to VZV; passive immunization should be administered as soon as possible after a recognised close exposure to VZV in a high-risk person who has never had varicella. Patients who develop zoster should be treated as soon as possible with acyclovir, famciclovir, or valacyclovir, which are administered orally. If zoster is severe, especially in immunocompromised patients, intravenous acyclovir can be administered, especially at the start of treatment surgery. Foscarnet is used to treat VZV infections that are resistant to ACV; the drug inhibits synthesis of VZV DNA polymerase.
Varicella-zoster Infections Emerging Drugs Chapters
This segment of the Varicella-zoster Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Varicella-zoster Infections Emerging Drugs
- NBP608: SK Bioscience
Further product details are provided in the report……..
Varicella-zoster Infections: Therapeutic Assessment
This segment of the report provides insights about the different Varicella-zoster Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Varicella-zoster Infections There are approx. 3+ key companies which are developing the therapies for Varicella-zoster Infections. The companies which have their Varicella-zoster Infections drug candidates in the most advanced stage, i.e. phase III include, SK Bioscience.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Varicella-zoster Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Varicella-zoster Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Varicella-zoster Infections drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Varicella-zoster Infections R&D. The therapies under development are focused on novel approaches to treat/improve Varicella-zoster Infections.
- In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
- Varicella-zoster Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Varicella-zoster Infections drugs?
- How many Varicella-zoster Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Varicella-zoster Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Varicella-zoster Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Varicella-zoster Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Curevo Vaccine
- GeneOne Life Science
- SK Bioscience
- NBP608
- CRV101
- GLS5100
Introduction
Executive Summary
Varicella-zoster Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Varicella-zoster Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Varicella-zoster Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Varicella-zoster Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
NBP608: SK Bioscience
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CRV101: Curevo Vaccine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
GLS5100: GeneOne Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Varicella-zoster Infections Key Companies
Varicella-zoster Infections Key Products
Varicella-zoster Infections - Unmet Needs
Varicella-zoster Infections - Market Drivers and Barriers
Varicella-zoster Infections - Future Perspectives and Conclusion
Varicella-zoster Infections Analyst Views
Varicella-zoster Infections Key Companies
Appendix
Executive Summary
Varicella-zoster Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Varicella-zoster Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Varicella-zoster Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Varicella-zoster Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
NBP608: SK Bioscience
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CRV101: Curevo Vaccine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
GLS5100: GeneOne Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Varicella-zoster Infections Key Companies
Varicella-zoster Infections Key Products
Varicella-zoster Infections - Unmet Needs
Varicella-zoster Infections - Market Drivers and Barriers
Varicella-zoster Infections - Future Perspectives and Conclusion
Varicella-zoster Infections Analyst Views
Varicella-zoster Infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Varicella Zoster Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Varicella Zoster Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Varicella Zoster Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Varicella Zoster Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
